Palisade Bio Expands Global Phase 2b ASCENTRA-UC Program with Health Canada CTA Clearance
Globe Newswire•23/09/2026•08:45 ET
0
Canadian clearance supports site activation and enrollment in the global study of once-daily oral PALI-2108
Primary efficacy results from approximately 204 patients with moderately to severely active ulcerative colitis expected in the second half of 2027
Get started
Create a free account to read the full story and Whiz Insights.